Questions to Ask About Ovarian Cancer Treatment

NCI's summary does not treat ovarian cancer alone. It covers three cancers together: ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer. The reason is not filing convenience.

All three share a hallmark. They spread early across the peritoneum. That is the lining of the abdominal cavity. They also appear to share an origin in Müllerian epithelium. High-grade serous cancer is the most common subtype. Many of these may begin in precursor lesions in the fimbriae. Those are the fringed ends of the fallopian tubes. The idea came out of risk-reducing surgeries in healthy women who carry BRCA1 or BRCA2 variants.

Primary peritoneal carcinomas that look the same under the microscope share molecular findings too. Those include loss or inactivation of the tumor-suppressor p53. They also include loss of the BRCA1 or BRCA2 proteins.

So these three are staged and treated alike. Since 2000, fallopian tube and primary peritoneal cancers have usually been included in ovarian cancer trials. That matters in practice. It widens the pool of trials a person may join.

"Ovarian cancer" is not one disease. Clear cell and endometrioid cancers linked to endometriosis have their own gene-expression signatures. So do mucinous subtypes. Stromal and germ cell tumors are separate again. Together they make up fewer than 10% of cases.

Cell type shows up directly in the outlook. A cell type other than mucinous or clear cell counts in a person's favor. Clear cell histology appears to carry a worse outlook. A large amount of transitional cell carcinoma appears to carry a better one.

Some scale for context. Epithelial ovarian carcinoma is among the most common gynecologic cancers. Almost 50% of all cases occur in women older than 65. It is the sixth most frequent cause of cancer death in women. For 2026 the American Cancer Society puts new US cases at 21,010 and deaths at 12,450. NCI republishes that projection rather than producing it.

Multivariate analyses give NCI a list of the most important favorable prognostic factors:

• Younger age.
• Good performance status.
• A cell type other than mucinous or clear cell.
• A well-differentiated tumor.
• Early-stage disease.
• Absence of ascites, meaning fluid in the abdomen.
• Lower disease volume before surgical debulking.
• Smaller residual tumor after primary cytoreductive surgery.
• A BRCA1 or BRCA2 variant.

That last one surprises people. A BRCA variant raises the risk of getting ovarian cancer. Yet it sits on the favorable side once cancer exists. Case-control studies suggest women with BRCA1 and BRCA2 variants respond better to chemotherapy. The comparison is with women whose ovarian cancer is sporadic. The proposed reason is a fault in homologous DNA repair inside those tumors. That fault makes them more sensitive to chemotherapy.

Two entries on that list are surgical, not biological. One is disease volume before debulking. The other is residual tumor after cytoreductive surgery. Both depend on what the operation achieved. That makes the surgical report worth reading closely.

About 20% of ovarian cancers are familial. Most of those are linked to BRCA1 or BRCA2. Several other genes are implicated too. NCI lists other risk factors as well. A first-degree relative with the disease. Lynch syndrome. Endometriosis. Hormone replacement therapy after menopause. High body mass index. And tall height.

Early disease has its own ranking. For stage I, the most important factor for relapse is grade. Next comes dense adherence. Then large-volume ascites.

The number attached to that is worth having. If the tumor is grade 3, densely adherent, or stage IC, the chance of relapse and death from ovarian cancer runs as high as 30%.

Stage I also has a distinct biology. Stage I tumors include many low-grade serous cancers. Those arise differently from high-grade serous cancers. High-grade serous disease usually shows up at stage III or IV.

Stage II sits awkwardly in between. Recurrence rates for stage II patients in early-stage trials ran high. So Gynecologic Oncology Group trials have grouped stage II with more advanced stages since 2009. Stage I remains a separate category for treatment planning.

Surgery followed by platinum-based chemotherapy is the usual shape of treatment, but not for everyone. NCI says that where the tumor is well or moderately well differentiated and the disease is stage IA or IB, surgery alone may be adequate, provided the staging operation was thorough. Grade, cell type and how completely you were staged all move that line. The options NCI lists for advanced disease are variations on how surgery and chemotherapy get arranged.

• Surgery followed by platinum-based chemotherapy.
• Surgery before or after platinum-based chemotherapy, with or without consolidation therapy.
• Surgery before or after chemotherapy, adding bevacizumab to induction or consolidation.
• Surgery after chemotherapy, adding HIPEC — heated chemotherapy delivered into the abdomen during the operation.
• Surgery before or after chemotherapy, adding a PARP inhibitor to induction or consolidation.

So the questions here are about order, and about additions. Does surgery come first, or chemotherapy? Is bevacizumab being added, and why? Is a PARP inhibitor planned? And does that depend on a BRCA or homologous repair result?

One note on method is worth knowing before reading trial numbers. A Gynecologic Cancer InterGroup meta-analysis pulled individual data from 17 randomized trials. Each had at least 60 newly diagnosed patients. They were published from 2001 through 2016. The analysis concluded that progression-free survival is not an adequate stand-in for overall survival here. No PARP inhibitor trials were included in it.

This is the part most likely to differ from expectation.

NCI describes the CA-125 assay as having low specificity and low sensitivity. Repeated CA-125 monitoring during treatment for recurrence may be useful. But the summary says the net benefit has not yet been determined.

On follow-up after the first course of treatment, the language is blunter still. There is little guidance. And neither early detection by imaging, nor early detection by a CA-125 rise, has been shown to change outcomes.

That is not an argument against having the test. It is an argument for asking what a given CA-125 result would actually change.

• Is this ovarian, fallopian tube, or primary peritoneal in origin — and does it change trial eligibility?
• What is the exact histologic subtype and grade?
• Is there ascites, and how much?
• For stage I: is it grade 3, densely adherent, or stage IC?
• What was the residual tumor after surgery, in measurable terms?
• Has germline and tumor testing for BRCA1, BRCA2, and other genes been done?
• Does surgery come before or after chemotherapy here, and why that order?
• Is bevacizumab, HIPEC, or a PARP inhibitor part of the plan?
• What would a rising CA-125 change, given that early detection has not been shown to alter outcomes?

See ovarian cancer for the overview and cancer staging for how these stage groups are built. This page is a question list drawn from NCI. It does not recommend a treatment.

• NCI PDQ — Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment, health professional version
• American Cancer Society — Cancer Facts & Figures